Recently, Zhejiang Langhua Pharmaceutical Co., Ltd. (hereinafter refer as Langhua Pharmaceutical) has successfully provided support and services for the scale-up production of clinical samples of VivaVision’s VVN001. The successful implementation of VVN001 clinical sample supportive service confirms the vertical client diversion effect of Viva Biotech from the front-end of new drug R & D, and further highlights the strategic synergy between Viva Biotech and Langhua Pharmaceutical in the fields of R & D and the production of innovative drugs.

As one of the key enterprises that invested and incubated by Viva Biotech, VivaVision is focusing on the R&D of innovative drugs for the treatment of ophthalmic diseases. The company is equipped with world-leading R&D ability and primary pipeline in the ophthalmic field. In April 2021, VivaVision announced the completion of a 300 million yuan Series D financing, which was led by Sequoia Capital. Its first pipeline that entered into the clinical stage, VVN001 (the second-generation LFA-1 antagonist), is carrying out the Phase II clinical study on the treatment of dry eye in the United States.

Dr. Jianguo Ma, CEO of Langhua Pharmaceutical said: "Langhua is much honored to provide support and services for VivaVision. We are very pleased to witness VivaVision’s growth and its pipeline expansion. In the future, we will continue to work along with Viva Biotech, to promote VivaVision’s clinical development, and to develop and produce better therapeutic drugs for patients with ophthalmic diseases.

"By the end of 2020, Viva Biotech has invested and incubated nearly 70 biotech start-ups, with a total of 125 pipelines, of which more than 50% of the pipelines have entered the PCC/IND-Enabling stage, and 11 pipelines have entered the clinical stage. These promising biotech companies and pipelines will become the critical advantages and prerequisites for subsequent CMC/CDMO vertical client diversion.

Viva Biotech reached the strategic integration with Langhua Pharmaceutical in November 2020. Taking the advantage front-end client flow, Viva Biotech will continue to promote the integration process with Langhua, by introducing CMC's relevant business capabilities and CMC’s core team, and combining Langhua's mature and well-established CDMO platform, to further strengthen the capabilities of both parties in drug research, development and production. What’s more, Viva will continue to forge a comprehensive one-stop drug service and production platform, and help global biotech innovators fulfill the transformation from "0" to "1".

About Viva Biotech

Viva Biotech’s mission is to become a cradle for innovative biotechnology companies from around the world. We have developed a scalable business model combing conventional cash-for-service (CFS) CRO work and a unique investment unit with a combination of equity-for-service (EFS) and traditional cash investment. Under the CFS model, Viva provides a one-stop service for novel drug discovery and manufacturing to global pharmaceutical clients. The EFS unit is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. As of December 31, 2020, Viva Biotech has provided drug discovery and production services to 1,252 pharmaceutical clients worldwide, and incubated/invested 67 biotech companies.

Viva Biotech has already completed the substantial acquisition of Langhua Pharmaceutical, a CDMO, and SYNthesis, a chemistry CRO company. We will continue building a one-stop service platform for novel drug discovery and manufacturing and assisting global biotech innovators to pursue the “0” to “1” transformation. For more information, please visit

About Langhua PharmaceuticalZhejiang Langhua Pharmaceutical Co., Ltd., the subsidiary of Viva Biotech Holding, is a leading company in the field of innovative drug discovery. As a fast-growing CDMO company, Langhua is committed to providing global innovative drug partners with an efficient, flexible and high-quality one-stop CMC (Chemistry, Production and Control) solutions for small molecule APIs and formulations from preclinical stage to commercialization. Langhua has three R&D centers in Shanghai, Taizhou and Ningbo. The R&D leaders in various fields are all returnees who have worked in MNCs for many years. They have rich experience in the process R&D, scale-up production and application of innovative drug raw materials and formulations. The production base, which is located in Taizhou, Zhejiang, has passed the site audit and inspection from different authorities like the US FDA, EU EDQ